Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,773 shares of the biopharmaceutical company's stock after selling 27,674 shares during the quarter. Great Lakes Advisors LLC's holdings in Ultragenyx Pharmaceutical were worth $1,328,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. UMB Bank n.a. grew its holdings in Ultragenyx Pharmaceutical by 118.8% during the 4th quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 329 shares in the last quarter. Covestor Ltd raised its stake in Ultragenyx Pharmaceutical by 392.1% during the third quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 596 shares in the last quarter. Van ECK Associates Corp raised its stake in Ultragenyx Pharmaceutical by 34.0% during the fourth quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 400 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 3,182.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 1,623 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 38.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company's stock worth $95,000 after buying an additional 548 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider John Richard Pinion sold 4,173 shares of the business's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the transaction, the insider now owns 89,268 shares of the company's stock, valued at $4,799,047.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider John Richard Pinion sold 4,173 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the sale, the insider now directly owns 89,268 shares in the company, valued at approximately $4,799,047.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the sale, the executive vice president now directly owns 252,823 shares of the company's stock, valued at approximately $12,623,452.39. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,116 shares of company stock worth $1,645,983. Corporate insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded up $0.50 on Wednesday, reaching $41.08. 505,027 shares of the stock traded hands, compared to its average volume of 759,852. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $54.98. The company has a fifty day moving average price of $44.75 and a 200-day moving average price of $44.81. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -5.12 and a beta of 0.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million during the quarter, compared to analysts' expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. The firm's revenue was up 8.3% compared to the same quarter last year. During the same period last year, the company earned ($2.33) earnings per share. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on RARE shares. Royal Bank of Canada started coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They issued an "outperform" rating and a $77.00 price target for the company. Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $111.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, May 6th. Robert W. Baird boosted their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. raised their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an "overweight" rating in a report on Monday, March 18th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and an average price target of $87.85.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.